(Taken directly from the application) The objective of this Core Unit is to provide investigators in the field on hematopoietic stem cell biology and gene therapy access to baboons and dogs to test novel concepts before application in humans. The Core Unit will provide three main functions. 1) Provision of a facility for stem cell transplantation in baboons and assistance with the planning and execution of experiments in baboons and dogs. 2) Bone marrow and peripheral blood harvests and CD34 cell selections and transductions. 3) Follow-up of transplanted animals using flow cytometric analysis of hematopoietic subpopulations. To allow monitoring of ex vivo manipulated stem cells after infusion into irradiated animals, cells will be genetically marked. All animals will receive an intravenous catheter that is connected via a tether system to the outside of the cage. This facilitates the daily administration of fluids and broad-spectrum antibiotics and will also be used for reinfusion of transduced baboon CD34 cells. Animals will be examined daily by the Core Unit directors and health status and treatment plan will be discussed with specially trained personnel at the Primate Center. The directors of this Core Unit have extensive experience in conducting stem cell transplantation studies in the baboon. The Primate Center at the University of Washington has set aside a special room for transplantation studies in baboons to accommodate the intensive care required for these studies and the staff at the Primate Center is specially trained to work with baboons involved in stem cell transplantation studies.

Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Sorror, Mohamed L; Gooley, Ted A; Maclean, Kirsteen H et al. (2018) Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. Bone Marrow Transplant :
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243
Roesch, Ferdinand; OhAinle, Molly; Emerman, Michael (2018) A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology 15:26
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Gust, Juliane; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 7:1404-1419
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020

Showing the most recent 10 out of 267 publications